Post-effective amendment to a registration statement that is not immediately effective upon filing

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)

v3.22.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) - USD ($)
Convertible Series A Preferred Stock [Member]
Preferred Stock
Convertible Series B-1A Preferred Stock [Member]
Preferred Stock
Convertible Series B-1 Preferred Stock [Member]
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Retroactive application of reverse recapitalization $ (1,000,000) $ (316,848) $ (1,000) $ 31,000 $ (21,000)   $ 8,000
Retroactive application of reverse recapitalization (in shares) (1,000)   (1,050,695) 30,563,009      
Balance (as previously reported) at Dec. 31, 2019 $ 1,000   $ 1,000 $ 11,000 33,539,000 $ (38,403,000) (4,851,000)
Balance (as previously reported) (in shares) at Dec. 31, 2019 1,000,000 316,848 1,050,695 10,686,191      
Beginning balance at Dec. 31, 2019       $ 42,000 33,518,000 (38,403,000) (4,843,000)
Beginning balance (in shares) at Dec. 31, 2019       41,249,200      
Common stock issued         2,579,000   2,579,000
Common stock issued (in shares)       542,875      
Series B-2 convertible preferred stock issued         50,000   50,000
Series B-2 convertible preferred stock issued (in shares)       13,168      
Common stock issued to settle note conversion       $ 1,000 3,961,000   $ 3,962,000
Common stock issued to settle note conversion (in shares)       1,138,199     1,138,199
Common stock issued to settle accounts payable         145,000   $ 145,000
Common stock issued to settle accounts payable (in shares)       30,020      
Warrants issued as compensation for services         5,383,000   5,383,000
Stock-based compensation         730,000   730,000
Net income (loss)           (51,777,000) (51,777,000)
Ending balance at Dec. 31, 2020       $ 43,000 46,366,000 (90,180,000) (43,771,000)
Ending balance (in shares) at Dec. 31, 2020       42,973,462      
Common stock issued       $ 1,000 9,623,000   $ 9,624,000
Common stock issued (in shares)       915,454      
Proceeds from issuance of common stock for exercise of warrant (in shares)             516,025
Reclassification of settlement liability upon issuance of warrant         60,852,000   $ 60,852,000
Effect of Merger and recapitalization, net of redemptions and issuance costs       $ 2,000 (26,618,000)   (26,616,000)
Effect of Merger and recapitalization, net of redemptions and issuance costs (in shares)       2,529,730      
Common stock issued pursuant to PIPE financing, net of issuance costs       $ 1,000 8,099,000   8,100,000
Common stock issued pursuant to PIPE financing, net of issuance costs (in shares)       1,000,000      
Common stock issued for advisor services         4,850,000   4,850,000
Common stock issued for advisor services (in shares)       200,000      
Modification of option awards pursuant to Merger         1,015,000   1,015,000
Modification of warrants pursuant to Merger         2,330,000   2,330,000
Common stock and warrants issued in private placement, net of issuance costs       $ 3,000 27,356,000   27,359,000
Common stock and warrants issued in private placement, net of issuance costs (in shares)       2,727,273      
Issuance of common stock for exercise of warrants and Unit Purchase Options       $ 4,000 16,695,000   $ 16,699,000
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)       3,830,586     3,830,586
Common stock issued for consulting services       $ 5,000 48,982,000   $ 48,987,000
Common stock issued for consulting services (in shares)       4,634,045     4,834,045
Stock-based compensation         4,440,000   $ 4,440,000
Net income (loss)           (93,063,000) (93,063,000)
Ending balance at Dec. 31, 2021       $ 59,000 $ 203,990,000 $ (183,243,000) $ 20,806,000
Ending balance (in shares) at Dec. 31, 2021       58,810,550